The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD). PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of CHD.

Original languageEnglish (US)
Pages (from-to)S172-S177
JournalJournal of lipid research
Issue numberSUPPL.
StatePublished - Apr 2009


  • Hypercholesterolemia
  • Low density lipoprotein
  • Low density lipoprotein receptor
  • Proprotein convertase subtilisin-like/ kexin type 9

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology


Dive into the research topics of 'PCSK9: A convertase that coordinates LDL catabolism'. Together they form a unique fingerprint.

Cite this